Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis begins new phase III trial of MS treatment

Sanofi-aventis begins new phase III trial of MS treatment

28th October 2010

Sanofi-aventis has commenced a phase III clinical trial of its new drug teriflunomide as an adjunct therapy against multiple sclerosis.

The company has initiated the international Teracles study, which will gauge the efficacy of its drug as an adjunct to interferon beta among 1,455 relapsing multiple sclerosis patients.

It expects to enrol its first patient in the placebo-controlled trial before the end of this year, with the study set to conclude once the last recruited participant has received treatment for at least 48 weeks.

Dr Marc Cluzel, executive vice-president for research and development at Sanofi-aventis, said: "Initiation of the Teracles study is a tremendous milestone as it is the first ever phase III study of an oral drug in adjunct therapy to be launched in MS."

This comes as part of a wider phase III clinical development programme for teriflunomide, which also includes evaluation of the drug as a monotherapy.

Data from a two-year study of the treatment was published by Sanofi-aventis earlier this month, showing its efficacy in reducing relapse rates among sufferers.ADNFCR-8000103-ID-800198906-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.